Mark Cuban’s US Pharma Ventures: Ally Or Gadfly In The Mix For Indian Firms?
Executive Summary
Mark Cuban’s newly launched online pharmacy and pharmacy benefit manager operation in the US has sparked interest in India. Can the billionaire entrepreneur’s venture punch above its weight and should Indian firms be watchful?
You may also be interested in...
Strides CEO: US COMPETES Act Creates Quality Differentiator
The $1-10m penalties prescribed on erring global manufacturers in the US COMPETES Act will create quality differentiators, Strides CEO R Ananthanarayanan tells Scrip. He also discusses the potential that Mark Cuban’s firm holds for Indian companies and Strides' evaluation of upcoming HIV therapies.
Mark Cuban’s Generics Company Launches Online Pharmacy
Mark Cuban’s generics venture has launched its online pharmacy in the US, highlighting in particular three products – imatinib, mesalamine and colchicine – that it says “epitomize the pharmacy’s striking savings.”
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.